文献速递胃肠动力与功能性疾病消化道肿瘤与早癌胰腺与胆道疾病

GLP-1受体激动剂在2型糖尿病患者中的胃肠与肝胆安全性

Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.
PubMed 文献 · Am J Gastroenterol · 2025-09-03

基于TriNetX网络的回顾性队列研究,2010至2020年经1:1倾向评分匹配后每组纳入230415例2型糖尿病患者,比较GLP-1受体激动剂与其他口服降糖药的胃肠肝胆结局。GLP-1受体激动剂与胃轻瘫(HR 1.591,P<0.001)和肠套叠(HR 1.383,P=0.025)风险升高相关,未增加急性胰腺炎、胆囊炎或胆囊切除术风险,且与胰腺、胃、食管、结直肠癌风险降低相关,但无法推断因果关系。

要点

  • GLP-1受体激动剂与胃轻瘫(HR 1.591)和肠套叠(HR 1.383)风险升高相关。
  • 未增加急性胰腺炎、胆囊炎或胆囊切除术风险。
  • 与胰腺、胃、食管、结直肠癌风险降低相关,但无法推断因果关系。

核心结论

  • GLP-1受体激动剂治疗未增加大多数严重胃肠或肝胆结局风险,但需警惕易感人群的胃轻瘫和肠套叠。

研究设计与样本

  • 回顾性队列研究,使用TriNetX网络,2010至2020年,经1:1倾向评分匹配后每组纳入230415例2型糖尿病患者,比较GLP-1受体激动剂与其他口服降糖药,评估5年胃肠和肝胆结局的风险比。

主要发现

  • GLP-1受体激动剂与胃轻瘫风险升高相关(HR 1.591,P<0.001)。
  • GLP-1受体激动剂与肠套叠风险升高相关(HR 1.383,P=0.025)。
  • 两组急性胰腺炎、胆囊炎或胆囊切除术率无显著差异。
  • GLP-1受体激动剂与胰腺癌(HR 0.897,P=0.038)、胃癌(HR 0.838,P=0.034)、食管癌(HR 0.741,P=0.001)和结直肠癌(HR 0.870,P=0.001)风险降低相关,但无法推断因果关系。
  • 胆道癌或肝细胞癌无显著差异。

临床怎么用

  • 在2型糖尿病患者中使用GLP-1受体激动剂时,应关注胃轻瘫和肠套叠的潜在风险,尤其是易感个体。

局限性

  • 无法推断因果关系。
  • 需要更长期研究以充分评估癌症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To evaluate the long-term gastrointestinal (GI) and hepatobiliary safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus, compared with other oral antidiabetic medications. METHODS: A retrospective cohort study using the TriNetX network was conducted between 2010 and 2020. After 1:1 propensity score matching, 230,415 patients were included in each group (GLP-1 RAs vs oral antidiabetes mellitus medications). Hazard ratios (HRs) for GI and hepatobiliary outcomes were assessed over 5 years. RESULTS: Among 230,415 matched patients per group, GLP-1 RA use was associated with a higher risk of gastroparesis (HR 1.591, P < 0.001) and intussusception (HR 1.383, P = 0.025) compared with oral antidiabetic therapy. There were no significant differences in acute pancreatitis, cholecystitis, or cholecystectomy rates between groups. Conversely, GLP-1 RA therapy was not associated with increased incidence of GI cancers. Lower hazard ratios were observed for pancreatic (HR 0.897, P = 0.038), gastric (HR 0.838, P = 0.034), esophageal (HR 0.741, P = 0.001), and colorectal cancer (HR 0.870, P = 0.001), although causality cannot be inferred. No significant differences were observed in biliary cancer or hepatocellular carcinoma. DISCUSSION: In this large real-world cohort study, GLP-1 RA therapy was not associated with increased risk of most serious GI or hepatobiliary outcomes compared with other oral diabetes medications. These findings support the overall GI and hepatobiliary safety of GLP-1 RAs in patients with type 2 diabetes, while underscoring the need for vigilance regarding gastroparesis and intussusception in susceptible individuals. Longer-term studies are warranted to fully evaluate cancer risk.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Niu C, Sun K, Zhang J, et al. Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. Am J Gastroenterol. 2025. PMID: 40900093. doi:10.14309/ajg.0000000000003760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。